Sernova Corp T.SVA

Alternate Symbol(s): SEOVF

Healthcare Biotechnology

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

TSX:SVA - Post by User

Sernova Corp

<< Previous

Bullboard Posts

Next >>

Post by Sailboatdreamon Apr 05, 2023 8:03pm

350 Views

Post# 35382201

Total Compensation Indecent

This taken from the management circular on sedar. No wonder they want to create more common shares! Total comp invludes a hefty portion of shares and options.

Frank Holler - Executive Chair
2022: $912,750
2021: $66,188
2022: $37,792

Philip Toleikis - President & CEO
2022: $5,577,868
2021: $634,000
2020: $367,000

David Swetlow - CFO
2022: $3,285,144
2021: $344,838
2020: $183,750

Frank Shannon - VP Clinical & Regulatory
2022: $636,300
2021: $60,737 (likely partial year)
2020: NA

Chris Barnes - VP Investor Relations
2022: $339,401
2021: NA
2020: NA

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario